Loading clinical trials...
Loading clinical trials...
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Conditions
Interventions
carfilzomib
Locations
30
United States
Mayo Clinic Scottsdale
Scottsdale, Arizona, United States
Tower Cancer Research Foundation
Beverly Hills, California, United States
Therapeutic Research Institute of Orange County
Laguna Hills, California, United States
Rocky Mountain Blood and Marrow Transplant Program
Denver, Colorado, United States
Oncology & Hematology Assoc. of W. Broward
Tamarac, Florida, United States
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida, United States
Start Date
September 1, 2007
Primary Completion Date
January 1, 2013
Completion Date
July 1, 2013
Last Updated
May 2, 2017
NCT06152575
NCT06179888
NCT04973605
NCT05201781
NCT05862012
NCT06138275
Lead Sponsor
Amgen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions